A panel of independent advisers to the Food and Drug Administration on Tuesday cast doubt on the benefits of MDMA-assisted therapy for post-traumatic stress disorder, marking a pivotal moment for the booming field of psychedelic medicine.
If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.
If you want to read more News articles, you can visit our News category.
